The Obeticholic Acid Market is on a significant upward trajectory, propelled by the increasing prevalence of chronic liver diseases, notably Primary Biliary Cholangitis (PBC) and Non-Alcoholic Steatohepatitis (NASH). Obeticholic acid, a potent farnesoid X receptor (FXR) agonist, is gaining momentum as a targeted therapeutic option, especially where conventional treatments fail. Valued at USD...